An Open-Label Trial of Alemtuzumab in Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIPD).
Withdrawn prior to enrolment
Phase of Trial: Phase IV
Latest Information Update: 23 May 2017
At a glance
- Drugs Alemtuzumab (Primary)
- Indications Chronic inflammatory demyelinating polyradiculoneuropathy
- Focus Therapeutic Use
- 17 May 2017 Planned End Date changed from 1 Dec 2016 to 1 Aug 2016.
- 17 May 2017 Planned primary completion date changed from 1 Dec 2015 to 1 Aug 2016.
- 17 May 2017 Status changed from recruiting to withdrawn prior to enrolment.